HRTX Heron Therapeutics Inc

Price (delayed)

$10.2

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.52

Enterprise value

$1.01B

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...

Highlights
The quick ratio has soared by 80% from the previous quarter
The equity has dropped by 51% year-on-year and by 18% since the previous quarter
HRTX's gross profit is down by 42% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
101.91M
Market cap
$1.04B
Enterprise value
$1.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.49
Price to sales (P/S)
12.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.21
Earnings
Revenue
$83.03M
EBIT
-$235.87M
EBITDA
-$232.92M
Free cash flow
-$203.77M
Per share
EPS
-$2.52
Free cash flow per share
-$2.07
Book value per share
$1.57
Revenue per share
$0.84
TBVPS
$4.11
Balance sheet
Total assets
$404.25M
Total liabilities
$244.14M
Debt
$165.16M
Equity
$160.11M
Working capital
$284.68M
Liquidity
Debt to equity
1.03
Current ratio
4.47
Quick ratio
3.66
Net debt/EBITDA
0.11
Margins
EBITDA margin
-280.5%
Gross margin
51.5%
Net margin
-282%
Operating margin
-279.7%
Efficiency
Return on assets
-64.2%
Return on equity
-107.7%
Return on invested capital
-109.3%
Return on capital employed
-73.2%
Return on sales
-284.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
-3.23%
1 week
0.29%
1 month
-18.98%
1 year
-38.18%
YTD
-51.82%
QTD
-4.58%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$83.03M
Gross profit
$42.74M
Operating income
-$232.26M
Net income
-$234.14M
Gross margin
51.5%
Net margin
-282%
The net margin has dropped by 79% year-on-year and by 2.8% since the previous quarter
HRTX's operating margin has dropped by 74% year-on-year and by 2.3% since the previous quarter
HRTX's gross profit is down by 42% year-on-year and by 12% since the previous quarter
HRTX's revenue is down by 34% year-on-year

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
6.49
P/S
12.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.21
Heron Therapeutics's EPS has decreased by 12% YoY
The equity has dropped by 51% year-on-year and by 18% since the previous quarter
The P/B is 19% lower than the 5-year quarterly average of 8.0 and 15% lower than the last 4 quarters average of 7.6
HRTX's price to sales (P/S) is 77% less than its 5-year quarterly average of 51.9 and 32% less than its last 4 quarters average of 17.7
HRTX's revenue is down by 34% year-on-year

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's ROE has plunged by 87% YoY and by 22% from the previous quarter
Heron Therapeutics's return on sales has shrunk by 75% YoY and by 2.8% QoQ
The ROIC has plunged by 62% YoY
HRTX's ROA is down by 47% YoY and by 4.6% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 66% higher than its total liabilities
HRTX's total liabilities has surged by 125% year-on-year and by 113% since the previous quarter
The quick ratio has soared by 80% from the previous quarter
The debt is 3.2% greater than the equity
The equity has dropped by 51% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.